Company* |
University/ |
Type Of Agreement | Product Area | Details (Date) |
| | ||||
Ablynx NV* |
National Research Council of Canada |
Collaboration |
The work focuses on Nanobodies developed at the NRC that cross the blood-brain barrier |
They plan to develop drugs and diagnostics for central nervous system diseases, initially Alzheimer's disease; terms were not disclosed (5/26) |
Acambis plc |
Flanders Interuniversity Institute for Biotechnology (Belgium) |
Collaboration |
To develop a vaccine against both the A and B strains of influenza |
The goal is to generate a candidate that would protect against both strains, and would not require annual formulation changes (8/4) |
Advanced Cell |
The Burnham Institute |
Collaboration |
For research that aims to isolate stem cell- specific differentiation markers |
They will use particle display technology to identify markers for many of the lineages of cells that make up the human body (7/27) |
Amplimed |
University of Arizona |
License agreement |
Amplimed got rights to a porfolio of compounds, including the cancer agent FB642 |
A university-related company gets equity in Amplimed, along with potential milestone and royalty payments (8/9) |
Affymetrix |
Broad Institute of MIT and Harvard |
Agreement |
The institute will use the GeneChip Mapping 500K Set for genome-wide association studies |
The institute gained use under Affymetrix's early access program; the institute and collaborators intend to generate genotypes relevant to multiple diseases (7/21) |
Akubio Ltd.* |
U.S. Army |
Collaboration |
To develop improved systems for detecting bioterrorism agents |
The work will be done with the U.S. Army Medical Research Institute of Infectious Diseases and is being supported by $3M from the National Institute of Allergy and Infectious Diseases (5/17)# |
Albany |
National Institute of Neurological Disorders and Stroke |
Collaboration |
Two-year deal aimed at developing treatments for spinal muscular atrophy |
AMRI will provide medicinal chemistry services on a fee-for- services basis(7/11) |
Alnylam |
Max Planck Society (Germany) |
License amendment |
Amended deal reinforces Alnylam's exclusivity for the "Tuschl II" patent application |
The patent is one believed by the company to be fundamental for RNA interference; Alnylam will issue 270,000 shares to Max Planck and other co- wners of the technology (6/16) |
Alnylam |
University of Georgia |
Collaboration |
To discover and develop RNAi-based therapeutics for newly emerging strains of influenza virus |
Alnylam intends to discover siRNAs that target flu genes required for viral replication and have antiviral activity; terms of the deal were not disclosed(6/25) |
Ambion Inc.* |
MitoChek consortium |
Agreement |
Ambion will provide the consortium a genome-wide siRNA library targeting every human gene |
The European Union-funded consortium will use the library to research how cell division is regulated; terms of the deal were not disclosed (8/12) |
Applied |
National Institute of Genomic Medicine of Mexico |
Collaboration |
To establish an Applied Biosystems sequencing and genotyping unit at the institute |
They also will conduct research studies focused on health issues important to the Mexican population (7/25) |
Applied Imaging |
University of Vermont |
Collaboration |
To further develop and validate technology to detect and characterize circulating tumor cells in the blood |
Applied Imaging subsidiary CTC Inc. will work with the university in the deal, terms of which were not disclosed (5/26) |
Arrowhead |
Stanford University |
License agreement |
Arrowhead licensed a nanotech device designed to control the behavior of adult stem cells |
Arrowhead will fund additional research on the device in exchange for the right to exclusively license the technology (6/6) |
Artemis |
Max Delbruk Center for Molecular Medicine and the University of Wurzbur (both in Germany) |
Collaboration |
Three-year deal to develop and validate methods for the functional analysis of disease- related genes in transgenic rats |
The work will be jointly funded by Artemis and the RiNA RNA- Network; Artemis gets rights to resulting products through a license agreement with RiNA GmbH, an entity of the German government (7/19) |
Ascentia |
University of Washington |
Option agreement |
Ascentia got rights to a family of compounds potentially applicable to a number of diseases |
Terms of the option were not disclosed; the compounds are being developed for cancer, sepsis, autoimmune diseases and for use in vaccines (8/15) |
Avantogen |
University of Alabama at Birmingham |
Collaboration |
For preclinical studies of a vaccine for herpes simplex virus type 2 |
UAB will use the firm's GP1-0100 adjuvant with a live, attenuated HSV-2 vaccine candidate (6/7) |
BioCurex Inc.* |
Center for Cancer Care |
Collaboration |
Deal to develop and evaluate BioCurex's RECAF technology |
The technology is used in targeting cancer cells; terms of the deal were not disclosed (5/20) |
BioLineRx |
Weizmann Institute of Science (Israel) |
License agreement |
BioLineRx licensed BL-2040, a small-molecule drug candidate |
The compound may have applications in treating hypertension, obesity and metabolic syndrome; terms were not disclosed (6/20) |
Biolog Inc.* and |
NARA Institute (Japan) |
Collaboration |
They extended deal to phenotype and determine the function of each gene in the E. coli genome |
Work on the project began in November 2004; terms of the deal were not disclosed (7/26) |
BioSante |
Wake Forest University and Cedars Sinai Medical Center |
License agreement |
BioSante exercised its option to license triple-hormone contraception technology |
The technology covers combinations of estrogens and progestins with androgens; BioSante will make up- ront and maintenanace payments, along with potential milestones and royalties (8/10) |
Biosite Inc. |
Johannes Gutenberg University (Germany) |
License agreement |
Biosite got exclusive rights to caspase-1, a potential biomarker for cardiovascular disease |
Biosite is collaborating with the University of Mainz to investigate clinical applications; terms of the deal were not disclosed (8/22) |
Biosite Inc. BSTE) |
Cincinnati Children's Hospital Medical Center and Columbia University |
License agreement |
Biosite got rights to neutrophil gelatinase- associated lipocalin, a potential for identifying acute renal failure |
Biosite will make antibodies to NGAL; the NGAL immunoassay then will be tested on blood samples to assess its potential; terms biomarker of the exclusive license agreement were not disclosed (7/13) |
BioVeris Corp. |
University of Massachusetts at Amherst |
Option agreement |
BioVeris optioned rights to a vaccine candidate for Chlamydia |
Separately, BioVeris will sponsor up to $600,000 of research on the candidate at UMA through 2006; if optioned, UMA would get license fees and potential milestones and royalties (5/25) |
Biovitrum AB* |
Karolinska Institute (Sweden) |
Agreement |
Biovitrum will produce a protein for preclinical research based on a technique developed at the institute |
Biovitrum, on behalf of the Department of Woman and Child Health, will produce recombinant HMGB-1, which is implicated in inflammatory reactions (5/31) |
Cambria |
Northwestern University |
Collaboration |
To screen existing compounds for activity againstamyotrophic lateral sclerosis |
The work is being funded by a grant from the ALS Association (8/8) |
Catalyst |
Torrey Pines Institute for Molecular Studies |
License agreement |
Catalyst got rights to use technology for protease engineering, selection and optimization |
The license covers a protease selection technology, and solidifies and expands Catalyst's position in proteases (7/25) |
Cenix |
Instituto de Medicina Molecular (Portugal) |
Collaboration |
They intend to identify human genes required for the malaria infection process |
The work, using an vitro assay system at the institute, is being funded by European agencies (6/29) |
ChemDiv Inc.* |
Scripps Florida |
Collaboration |
They extended deal giving Scripps access to ChemDiv screening libraries |
Terms of the deal were not disclosed (7/21) |
Chlorogen Inc.* |
Rutgers University |
License agreement |
Chlorogen got exclusive rights to chloroplast transformation patents |
The deal also gives Chlorogen limited rights to certain future discoveries by Rutgers from research in the field (8/16) |
ChondroGene |
University of California at San Francisco |
Alliance |
Deal setting framework for collaborations applying the Sentinel Principle to new drugs and diagnostics |
The Sentinel Principle is the company's approach to detect and stage diseases or conditions from a blood sample; Chrondro- Gene would have rights or options to resulting products (8/10) |
ChondroGene |
Lam Wa EE Hospital and Island Hospital (both in Malaysia) |
Collaborations |
The hospitals will provide clinical samples in a variety of disease areas |
The hospitals eventually will offer their patients molecular diagnostic tests and services from ChondroGene (6/10) |
Ciphergen |
University of Kentucky |
Collaboration |
Ciphergen got exclusive rights to license discoveries; the focus is on ovarian cancer |
Ciphergen will provide its suite of proteomic solutions for biomarker discovery and development of assays to the effort; terms were not disclosed (8/24) |
CombiMatrix |
Biodesign Institute at Arizona State University |
Collaboration |
To develop a peptide array synthesizer using CombiMatrix's virtual- flask technology |
The institute is purchasing CombiMatrix equipment and funding development; any revenues would be shared (8/12) |
Corautus |
Caritas St. Elizabeth's Medical Center |
Agreement |
Corautus will provide its VEGF-2 product for evaluation in a Phase I trial in diabetic neuropathy |
Corautus would get rights in that indication; also, Corautus licensed certain technology, including the use of angiogenic growth factors in peripheral neuropathy; the center is entitled to up- ront, milestone and royalty payments (8/10) |
Crucell NV |
Naval Medical Research Center of the U.S. Navy |
Cooperative Research and Development Agreement |
To construct AdVac- based vaccines against anthrax and plague and test them in nonhuman primates |
Crucell got an option for exclusive rights to any vaccine that may result from the deal (8/17) |
Cytheris* |
New York University, the City University of New York and the Aaron Diamond AIDs Research Center |
License agreement |
Cytheris got rights to a family of immuno-modulating agents that activate NKT and dendritic cells |
Terms of the exclusive, worldwide deal were not disclosed (5/23) |
CytoGenix |
Imperial College London |
Collaboration |
For research studies using the company's antimicrobial nucleic acid compound |
College researchers will further elucidate the antimicrobial activity of CytoGenix's RBL-1 compound (8/9) |
CytoGenix |
University of Pennsylvania |
Agreement |
The university will perform animal studies for the company |
The tests will use the company's synDNA technology to test a DNA vaccine against smallpox (6/21) |
CytoGenix |
National Institutes of Health |
Evaluation license |
CytoGenix will conduct experiments using an HIV DNA vaccine |
The synthetic vaccine is derived from HIV gene sequences contained in an NIH plasmid; terms were not disclosed (5/25) |
Digene Corp. |
Georgetown University |
Settlement and license agreement |
They settled litigation relating to patents covering human papillomavirus |
Georgetown will get payments totaling $7.5M, and royalties on sales of 5% to 6% (7/14) |
Diversa |
Clemson University |
Collaboration |
To assess opportunities for Diversa enzymes in enhancing human nutrition |
The intitial focus is on evaluating the ability of protein supplements to improve stamina and alertness and reduce fatigue (6/2) |
DOR |
SRI International |
Collaboration |
SRI is assisting in the development of the recombinant ricin vaccine RiVax |
SRI will optimize the immune response to the vaccine and perform preclinical safety testing; terms were not disclosed (7/5) |
Duska |
Undisclosed European scientists |
License agreement |
Duska got exclusive rights to P2 receptor-based technology not disclosed (6/15) |
The technology is expected to have applicability in treating glaucoma; terms of the deal were |
Duska |
University of Pennsylvania |
Agreement |
Preclinical studies with ATPotent will be carried out at the university |
ATPotent, a liquid formulation of adenosine 5'-triphosphate, is being developed by Duska for treating male infertility (6/13) |
Enzo Biochem |
Ludwig Maximilians University (Germany) |
Acquisition |
Enzo acquired rights to a candidate drug and technology for use in the treatment of uveitis |
The drug, which has orphan status in Europe, has been in a small Phase I trial in Germany; terms of the deal were not disclosed (6/9) |
Galapagos NV |
High Q Foundation Inc. |
Collaboration |
Two-year deal to discover targets and develop drugs for Huntington's disease |
Galapagos may receive up to $3M in the deal, and has the option to further develop certain targets identified (8/12) |
Galapagos NV |
Leiden University (the Netherlands) |
Collaboration |
To pursue a small-molecule drug discovery program in arthritis |
The four-way collaboration also includes ZoBio BV and Pyxis Discovery BV (8/10) |
GeneGo Inc.* |
National Cancer Institute |
License agreement |
The NCI licensed GeneGo's MetaCore 2.5 platform |
The platform is used to mine high- throughput experimental data; terms were not disclosed (5/31) |
GenoMed Inc. |
International Disease Management Alliance |
Agreement |
GenoMed joined the alliance, which was formed to promote disease management |
Details on GenoMed's role in the alliance were not disclosed (7/13) |
Genospectra |
CRNS (France) |
Agreement |
To develop a panel of optimized delivery reagents |
Genospectra also gets an exclusive license to "MPG" technology developed at the CNRS, and to products resulting from the collaboration (7/19) |
Gilead Sciences |
Emory University |
Agreement |
Gilead and Royalty purchased Emory's royalty interest in the HIV drug emtricitabine (Emtriva) |
Emory got a one-time cash payment of $525M, with 65% of it coming from Gilead; Gilead is obligated to pay royalties on future sales to Royalty Pharma (7/18) |
Immunetrics |
University of Cologne (Germany) and the Ludwig Boltzmann Institute (Austria) |
Collaboration |
To discover biomarkers of inflammation for use in drug discovery and disease diagnosis and management |
The academic partners get access to Immunetrics' modeling platform; the universities are providing a database of human and animal data (6/6) |
InforSense |
National Cancer Institute |
Agreement |
The NCI will use the company's technology for high-throughput genetic data analysis |
The NCI will use the KDE Infor- Sense integrative analytics platform under a five-year deal; terms were not disclosed (8/30) |
Insilico |
German Resource Center for Genome Research |
Collaborattion |
To integrate various information for the use of research scientists |
The effort links the company's MASI database with the center's material index (6/1) |
IntegraGen |
Fondation Autisme (France) |
Agreement |
IntegraGen will use DNA samples collected by the foundation to validate its genetic test for autism |
IntegraGen is supporting the foundation with a donation and by helping to create a databank and repository of DNA samples (5/23) |
Intercell AG |
Aeras Global TB Vaccine Foundation |
Agreement |
Aeras will fund development of a prophylactic tuberculosis vaccine |
In return, Aeras will get a sublicense to the vaccine for a number of developing countries; SSI and Intercell retain rights elsewhere (6/27) |
Invitrogen |
The Scripps Research Institute |
Collaboration |
To develop improved methods for expression, isolation and character- ization of membrane proteins |
Invitrogen will have the right to commercialize resulting technologies (8/25) |
JPT Peptide |
Oregon Health & Science University |
Collaboration |
Deal to discover T-cell epitopes to accelerate the development of tuberculosis vaccines |
JPT, a subsidiary of Jerini AG, will apply its high-throughput peptide synthesis and screening platform in the effort (7/7) |
Kalypsys Inc.* |
The Scripps Research Institute |
Agreement |
Scripps will access Kalypsys' ultra-high- throughput screening technologies |
The technology will be used in Scripps' newly created site in Florida; terms were not disclosed (6/15) |
Lipid Sciences |
Washington Hospital Center and MedStar Research Institute |
Collaboration |
To broaden the scope of the company's HDL therapy platform |
The deal allows Lipid to expand the program into the area of HDL mimetic peptides; terms were not disclosed (8/25) |
Maas BiolAB |
Walter Reed Army Institute of Research |
Cooperative Research and Development Agreement |
Deal to develop cyclosporin neuroprotection in indications relevant to military casualties and homeland security |
They will further collaborate to develop Maas' cyclosporin formula NeuroSTAT in models of traumatic brain injury and nerve gas poisoning (7/12) |
Macrogen Inc.* |
National Institute of Toxicological Research (South Korea) |
Agreement |
Macrogen will provide gene expression analysis services to the NITR |
The services will use the Applied Biosystems Group Expression Array System; terms were not disclosed (8/9) |
Meridian |
National Institutes of Health |
License agreement |
Meridian got rights to recombinant parvovirus B19 vaccine technology |
The license went to Meridian subsidiary Viral Antigens Inc.; Meridian previously had a contract to manufacture the vaccine (7/7) |
MerLion |
Institute of Molecular and Cell Biology (Singapore) |
Collaboration |
Three-year deal to discover and develop cancer drugs; the initial focus is the Bcl-2 family of proteins |
IMCB will provide certain drug targets and projects; MerLion will provide natural product sample collections, and apply screening and chemistry skills; they will share resulting ownership (7/1) |
Mesoblast Ltd. |
Colorado State University |
Agreement |
CSU will perform preclinical studies of Mesoblast technology |
CSU will test universal stem cell technolgoy for bone regeneration under undisclosed terms (7/21) |
MicroIslet Inc. |
The Scripps Research Institute |
Collaboration |
They extended for two years work to develop islet cell transplantation therapies |
The focus is on diabetes; Micro-Islet is providing financial support and technical assistance, and has the option to retain all commercial rights (8/31) |
Millenium |
Massachusetts Institute of Technology |
License agreement |
Millenium got rights to technology for certain uses of growth factors |
Millenium plans to develop a specific combination of growth factors in its Autologous Clinical Tissue Engineering Systems for cartilage repair (8/30) |
NeoRx Corp. |
Scripps Florida |
Collaboration |
To discover small-molecule protein kinase inhibitors as therapeutic agents |
The goal is to identify potential cancer treatments (8/4) |
Neuren |
Walter Reed Army Institute of Research |
Expanded agreement |
The deal is for development of Neuren's NNZ-2566 for traumatic brain injury |
They will explore the use of Walter Reed's model for predicting clinical outcomes; Walter Reed will fund half of preclinical research; Neuren retains all rights outside the U.S. military (7/8) |
New River |
University of California at San Francisco |
License agreement |
New River got rights to an approach to improve the use of opioid analgesics by reducing tolerance development |
UCSF's Ernest Gallo Clinic and Research Center is entitled to a license fee and potential milestone and royalty payments (7/8) |
Nonlinear |
Australian Proteome Analysis Facility Ltd. |
License agreement |
The APAF purchased two licenses to the company's Progenesis Discovery v2005 |
The product is a 2-D gel image analysis platform; terms of the licenses were not disclosed (6/16) |
Odyssey Thera |
National Institutes of Health |
Agreement |
Odyssey gave the NIH access to human cell lines with PCA technology for screening biochemical pathways |
Odyssey is providing access to the NIH Chemical Genomics Center as part of the NIH's Molec- ular Libraries Roadmap Initiative (8/17) |
OriGene |
Massachusetts General Hospital |
Collaboration |
Deal to use OriGene's FlagArray platform for high- hroughput functional analysis of genes |
Terms of the deal were not disclosed (7/25) |
Orion Genomics |
Washington University |
Collaborations |
To discover biomarkers for use in development of tests for cancer |
They will look for "Second Code" biomarkers for tests to screen for cancer at an early stage and to help guide treatment (8/9) |
Orion Genomics |
Johns Hopkins University School of Medicine |
Collaboration |
To better understand the role of DNA's "Second Code" in colon cancer |
They will study DNA methylation with the goal of developing a diagnostic test for the cancer's early detection (6/7) |
Peregrine |
U.S. Army Medical Research Institute of Infectious Diseases |
Cooperative Research and Development Agreement |
USAMRIID will study the potential of Tarvacin in treating hemorrhagic diseases |
Peregrine will supply the anti- phospholipid therapy; it will be studied for hemorrhagic diseases resulting from Ebola and Marburg viral infections (7/21) |
Perlegen |
RIKEN (Japan) |
Collaboration |
They will use Affymetrix Inc. technology to conduct whole- enome association studies in Japan |
The goal is to identify the genetic causes of up to 47 common diseases; Perlegen's subsidiary in Japan will work with RIKEN (7/20) |
Perlegen |
Pritzker Neuro- psychiatric Disorders Research Consortium |
Collaboration |
Perlegen is conducting a high- density whole-genome association study of bipolar disorder |
Results of the work are expected to help diagnose and treat neuropsychiatric diseases; terms ofthe deal were not disclosed (7/14) |
Perlegen |
Women's Health Initiative |
Collaboration |
Deal to conduct a high-density whole- genome scan of single nucleotide polymorphisms |
The SNPs will be in relation to coronary heart disease, stroke and breast cancer, and combined postmenopausal hormone therapy; work is being funded by the National Heart, Lung and Blood Institute (6/30) |
Pharmacopeia |
Columbia University and Cold Spring Harbor Laboratory |
Amended license agreement |
The deal covers the company's ECLiPS tagging technology |
Pharmacopeia said it also resolved a prior dispute regarding payment of royalties under the initial deal; terms were not disclosed (5/26) |
Phogen Ltd. |
Cancer Research Technology Ltd. (UK) |
Agreement |
CRT will help commercialize Phogen's VP22 technology |
CRT will help identify partners and negotiate terms for the drug-delivery platform (8/1) |
Power3 Medical |
University of Texas M.D. Anderson Cancer Center |
License |
Power3 got rights to cancer technologies co-developed by the parties |
The technologies involve an early detection test, protein bio-markers and targets for drug- resistant cancer (8/9) |
Power3 Medical |
The Methodist Hospital Research Institute |
Agreement |
To search for bio- markers and develop diagnostic tests for neurodegenerative diseases |
The deal marks a continuation of work already under way between the parties; terms were not disclosed (7/19) |
PPD Inc. |
Duke University |
License agreement |
Duke got rights to develop a portfolio of geranylgeranyl trans- ferase inhibitors |
Duke will fund R&D, and would share equally with PPD any future payments by third parties (6/22) |
Prolexys |
Imperial College London |
Agreement |
Prolexys joined a consortium focused on developing drugs for treatment of latent tuberculosis infection |
The consortium is supported by a $20M grant to Imperial College from the Grand Challenges in Global Health initiative (7/28) |
Proteome |
Foundation for Innovative New Diagnostics (Switzerland) |
Collaboration |
Letter of intent to fast-track development of an antigen- based diagnostic for detecting active tuberculosis |
Proteome Systems' test would detect TB antigens and monitor disease progression and treatment response; details were not disclosed (6/21) |
pSivida Ltd. |
University of South Australia |
Collaboration |
Deal to evaluate pSivida's BioSilicon platform for drug delivery |
The university's Ian Wark Research Institute will evaluate the controlled- release technology under a six-month deal (6/20) |
RegeneRx Bio- |
Children's National Medical Center |
Collaboration |
To study the effects of thymosin beta 4 to treat degenerative muscle diseases |
The center will test TB4 in non- human models that have a disease similar to human Duchenne's muscular dystrophy and go on to develop cardiomyopathy (8/4) |
Rubicon |
Genome Institute of Singapore |
Agreement |
Rubicon will isolate and amplify genomic DNA in archived serum samples |
The samples are from 5,000 participants in a hepatitis B vaccine trial; GIS will use the DNA to discover genes relevant to HBV (7/21) |
Sareum |
The Institute of Cancer Research and Cancer Research Technology Ltd. (both in the UK) |
Collaboration |
To develop cancer drugs that target a biochemical pathway responsible for resistance to standard chemotherapeutics |
Sareum will use its Template Screening technology to identify compounds; it would share in any payments, milestones and royalties arising from resulting license deals (7/25) |
Serologicals |
Wisconsin Alumni Research Foundation |
License agreement |
Serologicals unit Chemicon International Inc. got nonexclusive rights to all WARF's stem cell technologies |
Chemicon intends to commercialize research products derived from human embryonic stem cell technology; terms of the deal were not disclosed (7/25) |
Sirna |
Massachusetts General Hospital |
Sponsored research |
For research into using siRNAs and related formulations as modulators of the retino-blastoma gene pathway |
The goal is to promote regrowth and differentiation of hair cells that under natural conditions do not grow or divide in adult mammals (6/13) |
Structural |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration |
Three-year deal to discovery therapies to treat the cause of cystic fibrosis |
SGX will generate lead compounds that "correct" the delta F508 form of the CFTR protein; SGX gets $15M in technology access, research and milestone payments, and is eligible for clinical milestone payments and royalties on sales (7/6) |
Targepeutics |
National Institutes of Health |
License agreement |
Targepeutics licensed patents relevant to its genetically engineered interleukin-13 platform |
The 10 patents give background rights for the platform; terms of the deal were not disclosed (8/17) |
Tm Bioscience |
University of Miami |
Supply agreement |
Tm will provide reagents to the university |
University researchers will use the technology in cystic fibrosis and Ashkenazi Jewish panel gene assays (7/27) |
TriPath Imaging |
Cancer Research Technology Ltd. (UK) |
License agreement |
TriPath got rights to a number of cancer diagnostic markers |
The markers, from the Minichromosome Maintenance protein family, have applicability in various solid tumors (8/22) |
U.S. BioDefense |
University of British Columbia (Canada) |
License agreement |
Option deal covering UBC's neural crest stem cell line and its use in human transplantation |
U.S. BioDefense got a six-month option to license worldwide rights to the patent; terms were not disclosed (7/6) |
Valentis |
Vanderbilt University |
License agreement |
Valentis gained rights to the Del-1 antibody and associated intellectual property |
Valentis had licensed rights to the Del-1 protein and gene in 1998; Del-1 is an angiogenic protein; terms were not disclosed (5/19)# |
Xenomics Inc. |
Lazzaro Spallanzani Institute(Italy) |
Agreement |
They created a joint venture, SpaXen, to research Xenomics' diagnostic technology for detecting infectious disease |
Licensing terms and royalties were covered in the deal, terms of which were not disclosed; the deal centers on Xenomics' Transrenal-DNA diagnostic technology (7/12) |
YM BioSciences |
University of Saskatchewan (Canada) |
License agreement |
YM got exclusive rights to a portfolio of small-molecule oncology compounds |
The compounds are believed to be highly potent chemopotentiators; terms were not disclosed (8/10) |
York Pharma |
Freie Universitat Berlin (Germany) |
Acquisition |
York acquired patents relating to sphingosine-1-phosphate |
The preclinical technology may have applications in hyperproliferative skin disorders such as acne; the university gets an up-front payment and potential royalties (7/19) |
| | ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
# Item occurred before the time frame of this chart but was not included in the previous chart. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | ||||
